IGF-1 LR3 provides continuous, supraphysiological IGF-1 receptor stimulation that doesn't replicate natural growth hormone dynamics
When tesamorelin is the more appropriate choice Tesamorelin is typically the preferred agent when: Visceral adipose tissue is the primary treatment target, particularly with associated metabolic comorbidities A clinician is working within a framework that prioritises FDA-approved agents The patient has HIV-associated lipodystrophy, the only approved indication A robust evidence base is required for clinical decision-making For general somatopause-related concerns gradual changes in body composition, sleep quality, and recovery the CJC-1295/ipamorelin combination remains more commonly used, primarily because of its flexible dosing profile and the preserved pulsatile GH release pattern
Sema+-MSTN+-ActA) showed similar reductions in their body weight (Fig
The 40 mg dose provides extended activity for intensive metabolic research
While universal deprescribing is unlikely to drive optimal results, it may make sense on an individual basis to explore discontinuation, lowering the dose, or increasing time between doses, as patients enter a maintenance phase with their treatment